Abstract
Our purpose was to determine the role of the aromatase enzyme in mediating the myotrophic and prostate enlarging effects of androgens. 10 month old Fisher 344 rats received Sham surgery or orchiectomy (ORX). One week following surgery animals were implanted with motorized micro‐infusion pumps to disperse anastrozole (ANA; aromatase inhibitor) or vehicle at a rate of 2.0 μl/hour. Animals received once weekly IM testosterone enanthate (TE; 7.0mg/week), trenbolone enanthate (TREN; 1.0mg/week), or vehicle. 28 days following pump implantation animals were sacrificed and the prostate and levator ani‐bulbocavernosus (LABC) muscle were excised. Group (n=3) Prostate (g) LABC (g) SHAM (a) 0.29±0.064 c 0.88±0.033 b,c,d,e,f,g ORX (b) 0.07±0.014 d,e 0.45±0.004 d,e,f,g ORX+ANA (c) 0.06±0.003 a,d,e 0.48±0.025 d,e,f,g ORX+TE (d) 0.31±0.037 b,c 1.20±0.034 a,b,c ORX+TE+ANA (e) 0.31±0.074 b,c 1.22±0.046 a,b,c ORX+TREN (f) 0.15±0.064 1.19±0.035 a,b,c ORX+TREN+ANA (g) 0.18±0.033 1.19±0.013 a,b,c Values are mean±SEM. Significance values are reported from one‐way ANOVA and Tukey posthoc group comparison; letters indicate p<0.05 vs. group. Our findings suggest that estradiol is not required for androgen mediated prostate enlargement. Further, inhibiting the aromatase enzyme did not blunt the myotrophic effects of androgens.Supported by VA Merit Award to SEB and VA Geriatrics Fellowship to DTB.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
